The nation of Zimbabwe has turned down a substantial American health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' demand for confidential biological samples.
This rejection was revealed after a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative has since explained that the United States was demanding access to genetic material for research and commercial purposes while refused to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for more dialogue to reach a deal agreeable to both sides so the country's vital HIV programme can continue.
Wider Implications
This rejection comes after a similar situation in Kenya, where a high court halted a related health funding agreement following concerns were raised about the safety of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance openness and accountability.
Based on reports, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the end products would be accessible to our population should a new health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems already set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing discussions with our American counterparts on how future collaboration could be designed in a manner that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that negotiations must proceed given that a large portion of the country's Aids initiatives were funded by foreign aid.
"Where specific concerns exist, such as those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal emphasises the ongoing challenges between receiving vital international aid and protecting a country's data in an ever more interconnected world.